SCHEMBL7082273

SCHEMBL7082273

CCOC(=O)Cn1c(C)c[nH]c(=O)c1=O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 5/20 0.48
GSK3A P49840 2/20 0.48
GSK3B P49841 2/20 0.48
RAB9A P51151 1/20 0.45
TSHR P16473 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
PIN1 Q13526 1/20 0.42
PIN4 Q9Y237 1/20 0.42
KMT2A Q03164 3/20 0.42
TDP1 Q9NUW8 2/20 0.41
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ELANE P08246 1/20 0.41
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7641949 0.75 SLC9A1 (0.57) ALDH1A1KDM4EGSK3AGSK3BRAB9A
SCHEMBL4163334 0.73 ALDH1A1 (0.50) ALDH1A1KDM4EGSK3AGSK3BRAB9A
SCHEMBL1988320 0.72 ALDH1A1 (0.66) ALDH1A1KDM4EGSK3AGSK3BRAB9A
SCHEMBL11286220 0.72 ALDH1A1 (0.45) ALDH1A1KDM4EGSK3AGSK3BRAB9A
SCHEMBL5855748 0.72 KMT2A (0.48) ALDH1A1KDM4EGSK3AGSK3BTSHR
SCHEMBL5885705 0.71 KDM4E (0.49) ALDH1A1KDM4EGSK3AGSK3BRAB9A
SCHEMBL4901672 0.70 ALDH1A1 (0.48) ALDH1A1KDM4EGSK3AGSK3BRAB9A
SCHEMBL7220909 0.69 KDM4E (0.51) ALDH1A1KDM4EGSK3AGSK3BRAB9A
SCHEMBL12709665 0.68 ALDH1A1 (0.60) ALDH1A1KDM4EGSK3AGSK3BRAB9A
SCHEMBL2828050 0.68 KDM4E (0.54) ALDH1A1KDM4EGSK3AGSK3BRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-05-03 US disclosed
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-05-03 US disclosed
WO-2005040137-A1 AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2005-05-06 WO disclosed
EP-1341784-A2 PROCESS FOR MAKING A THROMBIN INHIBITOR Merck & Co., Inc. (US) 2003-09-10 EP disclosed
US-20020103379-A1 Process for making a thrombin inhibitor MERCK SHARP & DOHME LTD. (GB) 2002-08-01 US disclosed
WO-2002046160-A2 PROCESS FOR MAKING A THROMBIN INHIBITOR MERCK & CO., INC. (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103379-A1 Process for making a thrombin inhibitor TFPI, TFPI2, F2 ALDH1A1 640/4885KDM4E 2578/4885GSK3A 2840/4885
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors F2, F12, SERPINC1 ALDH1A1 716/4885KDM4E 1302/4885GSK3A 2042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.